Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Early central vs. peripheral immunological and neurobiological effects of fingolimod-a longitudinal study.

Sehr T, Akgün K, Proschmann U, Bucki R, Zendzian-Piotrowska M, Ziemssen T.

J Mol Med (Berl). 2019 Jun 26. doi: 10.1007/s00109-019-01812-x. [Epub ahead of print]

PMID:
31243520
2.

Spectral Analysis of Heart Rate Variability: Time Window Matters.

Li K, Rüdiger H, Ziemssen T.

Front Neurol. 2019 May 29;10:545. doi: 10.3389/fneur.2019.00545. eCollection 2019.

3.

How the depth of processing modulates emotional interference - evidence from EEG and pupil diameter data.

Schreiter ML, Chmielewski WX, Mückschel M, Ziemssen T, Beste C.

Cogn Affect Behav Neurosci. 2019 Jun 12. doi: 10.3758/s13415-019-00732-0. [Epub ahead of print]

PMID:
31190135
4.

Review: Patient-reported outcomes in multiple sclerosis care.

D'Amico E, Haase R, Ziemssen T.

Mult Scler Relat Disord. 2019 May 27;33:61-66. doi: 10.1016/j.msard.2019.05.019. [Epub ahead of print] Review.

PMID:
31154262
5.

Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis".

Akgün K, Ziemssen T.

Mult Scler. 2019 May 30:1352458519854263. doi: 10.1177/1352458519854263. [Epub ahead of print] No abstract available.

PMID:
31144585
6.

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS.

Akgün K, Kretschmann N, Haase R, Proschmann U, Kitzler HH, Reichmann H, Ziemssen T.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 8;6(3):e555. doi: 10.1212/NXI.0000000000000555. eCollection 2019 May.

7.

Response to: Kobayashi et al.: "Erythroblast appearance associated with natalizumab" Multiple Sclerosis and Related Disorders 2019.

Akgün K, Bornhäuser M, Ziemssen T.

Mult Scler Relat Disord. 2019 Jul;32:114-115. doi: 10.1016/j.msard.2019.05.003. Epub 2019 May 13. No abstract available.

PMID:
31103833
8.

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting.

Rodriguez-Leal FA, Haase R, Akgün K, Eisele J, Proschmann U, Schultheiss T, Kern R, Ziemssen T.

Ther Adv Chronic Dis. 2019 Apr 19;10:2040622319835136. doi: 10.1177/2040622319835136. eCollection 2019.

9.

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.

Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV.

Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019. Review.

10.

Letter to the editor regarding "Therapeutic drug monitoring of natalizumab".

Proschmann U, Sehr T, Akgün K, Ziemssen T.

Mult Scler. 2019 Apr 3:1352458519837702. doi: 10.1177/1352458519837702. [Epub ahead of print] No abstract available.

PMID:
30943104
11.

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies.

Akgün K, Essner U, Seydel C, Ziemssen T.

J Cent Nerv Syst Dis. 2019 Mar 11;11:1179573519831997. doi: 10.1177/1179573519831997. eCollection 2019. Review.

12.

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.

Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Couto CA, Findlay JA, Cornelissen C; PANGAEA study group.

Neurol Neuroimmunol Neuroinflamm. 2019 Mar 7;6(3):e548. doi: 10.1212/NXI.0000000000000548. eCollection 2019 May.

13.

On the interrelation of 1/f neural noise and norepinephrine system activity during motor response inhibition.

Pertermann M, Mückschel M, Adelhöfer N, Ziemssen T, Beste C.

J Neurophysiol. 2019 May 1;121(5):1633-1643. doi: 10.1152/jn.00701.2018. Epub 2019 Feb 27.

PMID:
30811254
14.

The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System-A Review.

Ziemssen T, Siepmann T.

Front Neurol. 2019 Feb 12;10:53. doi: 10.3389/fneur.2019.00053. eCollection 2019. Review.

15.

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.

Cuker A, Bass AD, Nadj C, Agius MA, Steingo B, Selmaj KW, Thoits T, Guerreiro A, Van Wijmeersch B, Ziemssen T, Meuth SG, LaGanke CC, Thangavelu K, Rodriguez CE, Baker DP, Margolin DH, Jannsens A.

Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612. [Epub ahead of print]

PMID:
30785358
16.

Anodal tDCS affects neuromodulatory effects of the norepinephrine system on superior frontal theta activity during response inhibition.

Adelhöfer N, Mückschel M, Teufert B, Ziemssen T, Beste C.

Brain Struct Funct. 2019 Apr;224(3):1291-1300. doi: 10.1007/s00429-019-01839-3. Epub 2019 Jan 30.

PMID:
30701308
17.

Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.

Ziemssen T.

Neurodegener Dis Manag. 2019 Apr;9(2s):1-2. doi: 10.2217/nmt-2018-0048. Epub 2019 Jan 18.

PMID:
30657019
18.

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group.

JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.

PMID:
30644981
19.

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up.

Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akgün K.

Front Neurol. 2018 Dec 7;9:1071. doi: 10.3389/fneur.2018.01071. eCollection 2018.

20.

Exploring individual multiple sclerosis lesion volume change over time: Development of an algorithm for the analyses of longitudinal quantitative MRI measures.

Köhler C, Wahl H, Ziemssen T, Linn J, Kitzler HH.

Neuroimage Clin. 2019;21:101623. doi: 10.1016/j.nicl.2018.101623. Epub 2018 Dec 3.

21.

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.

Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akgün K.

Front Immunol. 2018 Nov 20;9:2669. doi: 10.3389/fimmu.2018.02669. eCollection 2018.

22.

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.

Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V, McNeill M, Chang I, Lima G, Elkins J; ENHANCE study investigators.

CNS Drugs. 2019 Jan;33(1):61-79. doi: 10.1007/s40263-018-0586-5.

23.

Multiple sclerosis registries in Europe - An updated mapping survey.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C.

Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. No abstract available.

PMID:
30384204
24.

International consensus on quality standards for brain health-focused care in multiple sclerosis.

Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G.

Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326. [Epub ahead of print]

PMID:
30381987
25.

Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Proschmann U, Akgün K, Ziemssen T.

Neurology. 2018 Oct 30;91(18):849-850. doi: 10.1212/WNL.0000000000006422. No abstract available.

PMID:
30373924
26.

Predictors of response to opicinumab in acute optic neuritis.

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch LJ, Leocani L, Freedman MS, Plant GT, Preiningerova JL, Ziemssen F, Massacesi L, Chai Y, Xu L; RENEW Study Investigators.

Ann Clin Transl Neurol. 2018 Aug 15;5(10):1154-1162. doi: 10.1002/acn3.620. eCollection 2018 Oct.

27.

How minimal variations in neuronal cytoskeletal integrity modulate cognitive control.

Beste C, Stock AK, Zink N, Ocklenburg S, Akgün K, Ziemssen T.

Neuroimage. 2019 Jan 15;185:129-139. doi: 10.1016/j.neuroimage.2018.10.053. Epub 2018 Oct 19.

PMID:
30347280
28.

Sudomotor Testing of Diabetes Polyneuropathy.

Krieger SM, Reimann M, Haase R, Henkel E, Hanefeld M, Ziemssen T.

Front Neurol. 2018 Sep 26;9:803. doi: 10.3389/fneur.2018.00803. eCollection 2018.

29.

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting.

Albrecht P, Bjørnå IK, Brassat D, Farrell R, Feys P, Hobart J, Hupperts R, Linnebank M, Magdič J, Oreja-Guevara C, Pozzilli C, Salgado AV, Ziemssen T.

Ther Adv Neurol Disord. 2018 Oct 5;11:1756286418803248. doi: 10.1177/1756286418803248. eCollection 2018. Review.

30.

Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential.

Klistorner A, Chai Y, Leocani L, Albrecht P, Aktas O, Butzkueven H, Ziemssen T, Ziemssen F, Frederiksen J, Xu L, Cadavid D; RENEW MF-VEP Investigators.

CNS Drugs. 2018 Dec;32(12):1159-1171. doi: 10.1007/s40263-018-0575-8.

31.

Multi-component relaxation in clinically isolated syndrome: Lesion myelination may predict multiple sclerosis conversion.

Kitzler HH, Wahl H, Eisele JC, Kuhn M, Schmitz-Peiffer H, Kern S, Rutt BK, Deoni SCL, Ziemssen T, Linn J.

Neuroimage Clin. 2018 May 31;20:61-70. doi: 10.1016/j.nicl.2018.05.034. eCollection 2018.

32.

Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" Multiple Sclerosis and Related Disorders 2017.

Akgün K, Kaufmann M, Ziemssen T.

Mult Scler Relat Disord. 2018 May;22:68-69. doi: 10.1016/j.msard.2018.03.012. Epub 2018 Mar 22. No abstract available.

PMID:
29604536
33.

Letter to the editor to the paper: "Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis".

Ziemssen T, Limmroth V.

Mult Scler Relat Disord. 2018 May;22:57-58. doi: 10.1016/j.msard.2018.03.013. Epub 2018 Mar 19. No abstract available.

PMID:
29574354
34.

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis.

Akgün K, Metz I, Kitzler HH, Brück W, Ziemssen T.

Ther Adv Neurol Disord. 2018 Mar 8;11:1756286418759895. doi: 10.1177/1756286418759895. eCollection 2018.

35.

Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology.

Koristka S, Kegler A, Bergmann R, Arndt C, Feldmann A, Albert S, Cartellieri M, Ehninger A, Ehninger G, Middeke JM, Bornhäuser M, Schmitz M, Pietzsch J, Akgün K, Ziemssen T, Steinbach J, Bachmann MP.

J Autoimmun. 2018 Jun;90:116-131. doi: 10.1016/j.jaut.2018.02.006. Epub 2018 Mar 2.

PMID:
29503042
36.

Dual-Tasking in Multiple Sclerosis - Implications for a Cognitive Screening Instrument.

Beste C, Mückschel M, Paucke M, Ziemssen T.

Front Hum Neurosci. 2018 Jan 31;12:24. doi: 10.3389/fnhum.2018.00024. eCollection 2018.

37.

Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach.

Haase R, Wunderlich M, Dillenseger A, Kern R, Akgün K, Ziemssen T.

Expert Opin Drug Saf. 2018 Apr;17(4):369-378. doi: 10.1080/14740338.2018.1437144. Epub 2018 Feb 13. Review.

PMID:
29436244
38.

An Innovative Technique to Assess Spontaneous Baroreflex Sensitivity with Short Data Segments: Multiple Trigonometric Regressive Spectral Analysis.

Li K, Rüdiger H, Haase R, Ziemssen T.

Front Physiol. 2018 Jan 22;9:10. doi: 10.3389/fphys.2018.00010. eCollection 2018.

39.

Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany.

Becker V, Heeschen V, Schuh K, Schieb H, Ziemssen T.

Ther Adv Neurol Disord. 2018 Jan 23;11:1756285617748845. doi: 10.1177/1756285617748845. eCollection 2018.

40.

Fatigue and Sleep in Multiple Sclerosis Patients: A Comparison of Self-Report and Performance-Based Measures.

Paucke M, Kern S, Ziemssen T.

Front Neurol. 2018 Jan 4;8:703. doi: 10.3389/fneur.2017.00703. eCollection 2017.

41.

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.

Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Medin J, Cornelissen C; PANGAEA study group.

Neurotherapeutics. 2018 Jan;15(1):190-199. doi: 10.1007/s13311-017-0595-y.

42.

Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod.

David OJ, Berwick A, Pezous N, Lang M, Tiel-Wilck K, Ziemssen T, Li P, Hara H, Schmouder R.

Clin Pharmacol Drug Dev. 2018 Feb;7(2):217-221. doi: 10.1002/cpdd.424. Epub 2017 Dec 19.

43.

Perceptions on the value of bodily functions in multiple sclerosis.

Heesen C, Haase R, Melzig S, Poettgen J, Berghoff M, Paul F, Zettl U, Marziniak M, Angstwurm K, Kern R, Ziemssen T, Stellmann JP.

Acta Neurol Scand. 2018 Mar;137(3):356-362. doi: 10.1111/ane.12881. Epub 2017 Dec 3.

PMID:
29205262
44.

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis.

Li K, Konofalska U, Akgün K, Reimann M, Rüdiger H, Haase R, Ziemssen T.

Front Neurosci. 2017 Oct 12;11:540. doi: 10.3389/fnins.2017.00540. eCollection 2017.

45.

Autonomic Dysfunction in Wilson's Disease: A Comprehensive Evaluation during a 3-Year Follow Up.

Li K, Lindauer C, Haase R, Rüdiger H, Reichmann H, Reuner U, Ziemssen T.

Front Physiol. 2017 Oct 10;8:778. doi: 10.3389/fphys.2017.00778. eCollection 2017.

46.

Response to: S. Sega-Jazbec et al.: "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis" Multiple Sclerosis and Related Disorders 2017.

Thomas K, Ziemssen T.

Mult Scler Relat Disord. 2017 Oct;17:177-178. doi: 10.1016/j.msard.2017.08.001. Epub 2017 Aug 9. No abstract available.

PMID:
29055453
47.

The role of phasic norepinephrine modulations during task switching: evidence for specific effects in parietal areas.

Wolff N, Mückschel M, Ziemssen T, Beste C.

Brain Struct Funct. 2018 Mar;223(2):925-940. doi: 10.1007/s00429-017-1531-y. Epub 2017 Oct 12.

PMID:
29026994
48.

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.

Ziemssen T, Thomas K.

Ther Adv Neurol Disord. 2017 Oct;10(10):343-359. doi: 10.1177/1756285617722706. Epub 2017 Aug 4.

49.

[Implementation of the National Guidelines for the treatment of Diabetes mellitus type 2 in secondary diabetes centers].

Marahrens L, Röck D, Ziemssen T, Kern R, Ziemssen F, Fritsche A.

Dtsch Med Wochenschr. 2017 Sep;142(18):e131-e139. doi: 10.1055/s-0043-111388. Epub 2017 Sep 8. German.

PMID:
28902377
50.

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.

Ziemssen T, Tumani H, Sehr T, Thomas K, Paul F, Richter N, Samara E, Spiegelstein O, Sorani E, Bar-Ilan O, Mimrod D, Hayardeny L.

J Neuroinflammation. 2017 Aug 31;14(1):172. doi: 10.1186/s12974-017-0945-z.

Supplemental Content

Loading ...
Support Center